One Company Wants to Own Every Lifeline

Published August 2025  |  EvilCorporations.com Investigative Desk

One in four people diagnosed with severe aortic regurgitation will die within a year if left untreated — and Edwards Lifesciences tried to buy the only other company on earth that could save them.

That is the core of what the Federal Trade Commission put on the record on August 6, 2025: a Fortune 500 medical device corporation, already sitting on the overwhelming majority of a related billion-dollar market, reached out and grabbed the single competitor developing a life-saving technology for patients who have no other options.

This is a story about a company that decided the best business strategy was to make sure no one else could compete with it — while 8 million Americans waited for a treatment that only these two companies were building.

The Technology They Wanted to Monopolize

Aortic regurgitation, or AR, is a condition where the heart’s aortic valve fails to close properly after each heartbeat, causing blood to leak backward into the heart. Over time, this destroys the heart muscle. It causes heart failure. It causes sudden cardiac death. The FTC complaint documents that approximately one in four people diagnosed with severe and symptomatic AR will die within a year if untreated.

The current FDA-approved treatment is open-heart surgery. Surgeons cut open the chest, stop the heart, and replace the valve. For younger, healthier patients, this is survivable. For older patients, frailer patients, and anyone with additional health conditions, this surgery carries unacceptable risk. The FTC is direct about this: open-heart surgery is not recommended for high-risk patients. For those people, there has been, until now, essentially nothing.

TAVR-AR — transcatheter aortic valve replacement for aortic regurgitation — is the answer. Instead of cracking open a chest, a physician guides an artificial valve through the patient’s femoral artery in the groin. No general anesthesia required. No stopped heart. Most patients spend one day in the hospital compared to three to seven days following open-heart surgery. The FTC called it “revolutionary.” It is the difference between life and death for patients who cannot survive the alternative.

Why You Can’t Just Use the Existing Technology

Edwards already dominates a related market: TAVR devices for aortic stenosis, which is a different valve condition involving calcium buildup. Its Sapien valve launched in 2011 and turned TAVR-AS into a multibillion-dollar market. Edwards commands the overwhelming majority of that market.

But those existing devices cannot treat AR patients. The reason is anatomical: TAVR-AS devices anchor themselves using calcium deposits in the diseased valve. AR patients have uncalcified valves. If you try to use an AS device on an AR patient, the valve can literally dislodge inside the heart — a potentially fatal condition called embolization. Doctors have tried it off-label. It fails. The FTC is explicit: “The structural heart industry and medical community similarly recognize that TAVR-AS devices are not viable substitutes for dedicated TAVR-AR devices.”

TAVR-AR devices use self-expanding frames engineered specifically to anchor without calcium. Building one requires entirely new science, years of clinical trials, and FDA approval. That process typically takes at least five years. There is no shortcut. There is no workaround. There is only the research, and there were only two companies doing it.

The Play: How Edwards Engineered a Monopoly Step by Step

Edwards did not stumble into a dominant position. The FTC complaint lays out a deliberate, sequential acquisition strategy. Edwards first acquired JC Medical, which owned J-Valve, one of the two TAVR-AR devices in active clinical trials. That acquisition put one competitor directly in Edwards’ pocket. Then, before even completing that deal, Edwards moved to acquire JenaValve, the maker of Trilogy, the other competitor.

Two competitors. Both acquired. Zero remaining competition. The FTC was explicit: “Should the Proposed Acquisition be consummated, the number of competitors in the TAVR-AR device market would shrink from two to one.” In a market where any new entrant would require a minimum of five years just to reach clinical trial stage, that is a monopoly in every practical sense.

The merging parties together accounted for the entirety of the TAVR-AR clinical trial market in the United States. JenaValve’s Trilogy had already completed its pivotal ALIGN-AR trial in March 2024. Edwards expected FDA approval for JenaValve’s device ahead of its own J-Valve product, meaning JenaValve would have held 100% of commercial sales during the window before J-Valve could reach market. By owning both, Edwards guaranteed it would face no competition at any stage: not in clinical trials, not at launch, not in the commercial market.

They Said No to Regulators. Repeatedly.

The FTC did not file this complaint immediately. Commission staff spent eight months attempting to negotiate a resolution. As early as November 2024, regulators asked Edwards whether it would agree to divest JC Medical — to give up one of its two TAVR-AR products in exchange for being allowed to proceed with the JenaValve acquisition. This proposal was renewed repeatedly, including in meetings with Bureau of Competition leadership and the Commission Chairman himself.

Edwards said no. Every single time. The FTC complaint is unambiguous: “Edwards repeatedly rejected the Commission’s outreach to divest JC Medical in order to clear the path for Edwards to consummate its proposed acquisition of JenaValve.” This was a calculated decision. Edwards knew exactly what the regulators wanted, understood why they wanted it, and refused anyway.

The Non-Financial Ledger: What This Costs in Human Terms

The FTC complaint is a legal document, filled with market definitions and antitrust standards. But underneath the procedural language is a population of real people: at least 8 million Americans over age 50 living with aortic regurgitation. They are not abstract consumers in a relevant product market. They are people watching their bodies fail. They are people who have already been told that the one treatment that exists — cracking open their chest — is too dangerous for them specifically. They are people who were, at the moment of this complaint, waiting on two companies to finish clinical trials that would save their lives. One of those companies wanted to absorb the other.

Think about what it means to be told you have a fatal heart condition and the treatment is too risky for you. Your doctor is not saying there is no cure. Your doctor is saying the cure exists, but your body cannot survive it. Then a new technology emerges: minimally invasive, no general anesthesia, one night in the hospital. Clinical trials are underway. Approval could come within years. For the first time, you are on the right side of a medical timeline. And then a corporation decides that it wants to own that timeline entirely.

The FTC complaint directly documents what competition between these two companies was producing for patients: a race to lower the “pacemaker rate,” meaning the percentage of TAVR-AR procedures that result in a patient needing an additional heart pacemaker implanted. That is a direct quality-of-life outcome. Every patient who receives a TAVR-AR device and does not need a subsequent pacemaker because the competing companies drove each other to build a better product: that is a life made less complicated, less medicalized, less burdened. Competition was doing that work in real time. Edwards wanted to stop the race by buying the only other runner.

The FTC identified another dimension: competition for clinical trial sites at major research institutions and for top TAVR specialists. This matters enormously. When two companies compete aggressively for the best research centers and the most experienced physicians, clinical data quality improves, enrollment speeds up, and patients gain access to the technology faster. When one company controls both products, there is no urgency. The patient waiting for FDA approval is not a competitive liability. They are simply waiting. The FTC complaint warns that “the pace of innovation in TAVR-AR devices is likely to slow” under consolidated ownership, and that “the risk of one of the valves being de-prioritized or abandoned rises.” That is a company’s cost-benefit calculation standing between a sick person and the treatment that could keep them alive.

Legal Receipts: The Exact Words They Filed in Federal Court

These are direct, verbatim statements from the FTC’s formal complaint. They are on the public record. Read them slowly.

“Approximately one in four people diagnosed with severe and symptomatic AR will die within a year if left untreated.”

FTC Complaint, Paragraph 3 — Describing the patient population Edwards sought to monopolize

“The Proposed Acquisition would substantially lessen competition or tend to create a monopoly in the U.S. TAVR-AR device market in the United States by eliminating vigorous head-to-head competition between Edwards/JC Medical and JenaValve.”

FTC Complaint, Paragraph 38 — The core antitrust charge

“If Edwards controls both Trilogy and J-Valve, the pace of innovation in TAVR-AR devices is likely to slow and the risk of one of the valves being de-prioritized or abandoned rises.”

FTC Complaint, Paragraph 7 — On the consequences of consolidated ownership

“Edwards repeatedly rejected the Commission’s outreach to divest JC Medical in order to clear the path for Edwards to consummate its proposed acquisition of JenaValve.”

FTC Complaint, Paragraph 20 — On Edwards’ eight months of refusal to negotiate

“The Proposed Acquisition therefore may substantially lessen competition or tend to create a monopoly in the TAVR-AR device market, resulting in reduced innovation, diminished product quality, and potentially increased prices for U.S. consumers.”

FTC Complaint, Paragraph 11 — Spelling out who pays the price

“There are no countervailing factors sufficient to offset the likelihood of competitive harm from the Proposed Acquisition. Respondents cannot demonstrate that new entry of TAVR-AR devices would be timely, likely, or sufficient to offset the anticompetitive effects of the Proposed Acquisition.”

FTC Complaint, Paragraph 12 — On why there is no self-correcting market mechanism here

Societal Impact Mapping

Public Health: When Monopoly Kills the Cure

The public health stakes here are not speculative. The FTC complaint identifies a population of at least 8 million Americans over age 50 living with aortic regurgitation. Of those, the patients with severe and symptomatic AR who are also ineligible for open-heart surgery represent the exact group that TAVR-AR was built to serve. These are people who are currently out of options. For them, the speed at which TAVR-AR reaches commercial approval is a matter of survival.

Competition between Edwards/JC Medical and JenaValve was actively accelerating that timeline. Both companies were enrolled in pivotal clinical trials simultaneously, competing for the best research sites, the most experienced specialists, and the cleanest clinical data. The FTC complaint documents that this competition drove measurable improvements: the race to lower pacemaker rates produced a directly better product for patients. Remove the competition, and that engine of improvement stops. A patient waiting for a safer, lower-complication valve does not receive one. They receive whatever version Edwards sees fit to develop on its own schedule.

The FTC flagged explicitly that under single ownership, one of the two valve products risked being de-prioritized or abandoned entirely. A corporation running two competing products within the same portfolio has every financial incentive to consolidate around a single product. If J-Valve gets shelved because Trilogy is further along, the clinical knowledge embedded in J-Valve’s trial, the patients who enrolled in that trial, and the researchers who built that device all contribute to zero additional treatment options. The market gives patients one valve. Edwards decides which one. Edwards decides when it reaches doctors. Edwards sets the price.

Economic Inequality: The Monopoly Price Always Lands on the Sick

The FTC complaint directly identifies “potentially increased prices for U.S. consumers” as a likely consequence of the merger. In a market where health insurance coverage, Medicare reimbursement rates, and out-of-pocket costs determine who can afford care, that language translates directly into which patients receive treatment and which ones do not. Medical devices with no competitors do not face price pressure. The manufacturer charges what the market tolerates, and in American healthcare, the market tolerates a great deal.

Edwards is already the dominant player in the existing TAVR market for aortic stenosis, controlling the overwhelming share of that multibillion-dollar market. The playbook for TAVR-AR was to replicate that dominance before a single competitor could establish itself commercially. Hospitals, insurance payers, and ultimately patients would negotiate with one supplier. The leverage would belong entirely to Edwards. The new technology, described by the FTC as “revolutionary” and as the only viable option for high-risk patients, would be priced accordingly.

This price dynamic does not fall evenly. Elderly patients on fixed incomes, patients in rural areas with limited hospital access, patients in states with weaker Medicaid programs: these populations bear the concentrated cost of monopoly pricing in medical devices. The innovation deficit matters too. A slower development timeline under reduced competitive pressure means that improved versions of TAVR-AR, with lower complication rates and wider eligibility criteria, take longer to reach the patients who need them most. The patients with the fewest resources and the least institutional power are always last in line when corporate profit determines the pace of medicine.

What Now? Who to Watch and What to Do

The FTC filed its formal complaint on August 6, 2025. An evidentiary hearing is scheduled for January 7, 2026. The Commission has put Edwards on notice that if the acquisition is allowed to proceed, the full range of remedies includes forced divestiture, a prohibition on combining the businesses, and ongoing monitoring at Edwards’ expense.

Regulatory Bodies Watching This Case

• Federal Trade Commission (FTC) — Filed the complaint; holds the authority to block or unwind the merger
• FDA — The agency whose clinical trial approval process is the structural barrier preventing new competitors from entering the TAVR-AR market for at least five years
• Department of Justice Antitrust Division — Parallel jurisdiction on merger enforcement; relevant if FTC action escalates to federal court
• Centers for Medicare and Medicaid Services (CMS) — The primary payer for the elderly patient population that TAVR-AR is designed to serve; monopoly pricing directly impacts federal healthcare spending

Corporate Roles to Track

• Edwards Lifesciences Corp. — Acquiring entity; the corporation that initiated the merger and refused eight months of federal negotiation
• JenaValve Technology, Inc. — The target being absorbed; maker of Trilogy, the device furthest along in FDA approval
• JC Medical (Edwards Subsidiary) — The first acquisition; maker of J-Valve; the product the FTC asked Edwards to divest as a condition of the JenaValve deal

The Ground Level: What Resistance Looks Like

Support patient advocacy organizations focused on cardiovascular disease access. Push your representatives on the Senate and House Judiciary and Health committees to hold hearings on medical device monopoly pricing. Support community health centers and mutual aid networks that fill the gaps when corporate pricing locks patients out of care. The FTC is doing its legal job here; your job is to make sure the political will exists for that legal job to matter. Contact the FTC at ftc.gov to submit public comments on this merger. The hearing is January 7, 2026. The window to make noise is now.